S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
Log in

Nephros Stock Forecast, Price & News

+0.09 (+1.10 %)
(As of 03/2/2021 12:00 AM ET)
Today's Range
Now: $8.28
50-Day Range
MA: $8.12
52-Week Range
Now: $8.28
Volume3,852 shs
Average Volume17,456 shs
Market Capitalization$81.68 million
P/E RatioN/A
Dividend YieldN/A
Nephros, Inc., a commercial-stage company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to health care, food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.
Nephros logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:NEPH
Phone201 343 5202
Year FoundedN/A



Sales & Book Value

Annual Sales$10.33 million
Book Value$0.95 per share


Net Income$-3,420,000.00


Market Cap$81.68 million
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.99 out of 5 stars

Medical Sector

61st out of 1,969 stocks

Surgical & Medical Instruments Industry

12th out of 169 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
+0.09 (+1.10 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NEPH News and Ratings via Email

Sign-up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Nephros (NASDAQ:NEPH) Frequently Asked Questions

Is Nephros a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nephros stock.
View analyst ratings for Nephros
or view top-rated stocks.

What stocks does MarketBeat like better than Nephros?

Wall Street analysts have given Nephros a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nephros wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Nephros?

Nephros saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 12,500 shares, an increase of 54.3% from the January 28th total of 8,100 shares. Based on an average trading volume of 19,400 shares, the short-interest ratio is presently 0.6 days.
View Nephros' Short Interest

When is Nephros' next earnings date?

Nephros is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Nephros

How were Nephros' earnings last quarter?

Nephros, Inc. (NASDAQ:NEPH) posted its quarterly earnings results on Sunday, February, 28th. The company reported ($0.08) EPS for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.03. Nephros had a negative net margin of 43.58% and a negative trailing twelve-month return on equity of 36.33%.
View Nephros' earnings history

How has Nephros' stock price been impacted by COVID-19 (Coronavirus)?

Nephros' stock was trading at $7.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NEPH shares have increased by 10.8% and is now trading at $8.28.
View which stocks have been most impacted by COVID-19

What guidance has Nephros issued on next quarter's earnings?

Nephros updated its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.31 million.

What price target have analysts set for NEPH?

2 Wall Street analysts have issued 1 year price objectives for Nephros' stock. Their forecasts range from $12.50 to $16.00. On average, they anticipate Nephros' stock price to reach $14.25 in the next year. This suggests a possible upside of 72.1% from the stock's current price.
View analysts' price targets for Nephros
or view top-rated stocks among Wall Street analysts.

Who are Nephros' key executives?

Nephros' management team includes the following people:
  • Mr. Andrew Astor, CEO, Pres, COO & Director (Age 64, Pay $355.61k)
  • Mr. Daniel S. D'Agostino, Chief Financial Officer (Age 54)
  • Ms. Joleen C. Turner, VP of Marketing & Bus. Devel.
  • Mr. Shane Sullivan, VP of Sales
  • Mr. Greg Lucas, Pres of Aether Water Systems

Who are some of Nephros' key competitors?

What is Nephros' stock symbol?

Nephros trades on the NASDAQ under the ticker symbol "NEPH."

Who are Nephros' major shareholders?

Nephros' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cowen Prime Services LLC (5.83%), Samjo Capital LLC (5.58%), HighTower Advisors LLC (0.56%) and Elkhorn Partners Limited Partnership (0.14%). Company insiders that own Nephros stock include Andrew Astor, Daron Evans and Oliver J Spandow.
View institutional ownership trends for Nephros

Which institutional investors are selling Nephros stock?

NEPH stock was sold by a variety of institutional investors in the last quarter, including Elkhorn Partners Limited Partnership.
View insider buying and selling activity for Nephros
or view top insider-selling stocks.

Which institutional investors are buying Nephros stock?

NEPH stock was purchased by a variety of institutional investors in the last quarter, including Samjo Capital LLC, Cowen Prime Services LLC, and HighTower Advisors LLC. Company insiders that have bought Nephros stock in the last two years include Andrew Astor, Daron Evans, and Oliver J Spandow.
View insider buying and selling activity for Nephros
or or view top insider-buying stocks.

How do I buy shares of Nephros?

Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nephros' stock price today?

One share of NEPH stock can currently be purchased for approximately $8.28.

How much money does Nephros make?

Nephros has a market capitalization of $81.68 million and generates $10.33 million in revenue each year. The company earns $-3,420,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Nephros have?

Nephros employs 25 workers across the globe.

What is Nephros' official website?

The official website for Nephros is www.nephros.com.

Where are Nephros' headquarters?

Nephros is headquartered at 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079.

How can I contact Nephros?

Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201 343 5202.

This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.